Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL15110 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL3058481 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL9133774 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL3197361 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL3200076 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL4769225 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL5830392 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL3171689 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL9756248 | 0.96 | TSHR (0.46) | — | |
| Ethylene Glycol SCHEMBL622577 | 0.96 | TSHR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113242860-B | Alkyl lithium aluminate as transalkylation reagent | 优美科股份公司及两合公司 | 2024-01-02 | — | — | CN | claimed |
| US-11384102-B2 | Lithium alkyl aluminates as alkyl transfer reagents | UMICORE AG & CO. KG (DE) | 2022-07-12 | — | — | US | claimed |
| EP-3894419-A1 | LITHIUM ALKYL ALUMINATES AS ALKYL TRANSFER REAGENTS | UMICORE AG & Co. KG (DE) | 2021-10-20 | — | — | EP | claimed |
| WO-2020120148-A1 | LITHIUM ALKYL ALUMINATES AS ALKYL TRANSFER REAGENTS | UMICORE AG. & CO. KG. (DE) | 2020-06-18 | — | — | WO | claimed |
| CN-106146446-B | Dapagliflozin semihydrate and its crystal form, preparation method and pharmaceutical composition | 杭州领业医药科技有限公司 | 2019-11-08 | — | — | CN | claimed |
| CN-108516966-A | Crystal form of Dapagliflozin and its preparation method and application | 浙江海正药业股份有限公司 | 2018-09-11 | — | — | CN | claimed |
| WO-2018142422-A1 | PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN | INDOCO REMEDIES LIMITED (IN) | 2018-08-09 | — | — | WO | claimed |
| EP-2498759-B1 | IMMEDIATE RELEASE TABLET FORMULATIONS | ASTRAZENECA AB (SE) | 2018-08-01 | — | — | EP | claimed |
| US-8716251-B2 | Pharmaceutical formulations containing an SGLT2 inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-06 | — | — | US | claimed |
| US-20130129819-A1 | Pharmaceutical Formulations Containing An SGLT2 Inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | claimed |
| US-20130034606-A1 | IMMEDIATE RELEASE TABLET FORMULATIONS | ASTRAZENECA UK LIMITED (GB) | 2013-02-07 | — | — | US | claimed |
| EP-2498759-A2 | IMMEDIATE RELEASE TABLET FORMULATIONS | Bristol-Myers Squibb Company (US) | 2012-09-19 | — | — | EP | claimed |
| WO-2011060290-A2 | IMMEDIATE RELEASE TABLET FORMULATIONS | Bristol-Myer Squibb Company (US) | 2011-05-19 | — | — | WO | claimed |
| EP-4431088-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DAPAGLIFLOZIN AND METFORMIN | Galenicum Health S.L.U. (ES) | 2024-09-18 | — | — | EP | disclosed |
| EP-4427742-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DAPAGLIFLOZIN AND METFORMIN | Galenicum Health S.L.U. (ES) | 2024-09-11 | — | — | EP | disclosed |
| CN-113242860-B | Alkyl lithium aluminate as transalkylation reagent | 优美科股份公司及两合公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-2139494-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE | Bristol-Myers Squibb Company (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116179-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234366-A1 | Dapagliflozin propylene glycol hydrate; diabetes; immediate release; sodium dependent glucose transporter (SGLT2) inhibitor | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | disclosed |